Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 3
1973 1
1974 4
1975 1
1977 1
1979 1
1981 1
1982 1
1983 2
1984 1
1985 1
1987 1
1988 2
1989 1
1990 1
1991 1
1994 2
1996 1
1997 2
1999 2
2000 5
2001 2
2002 3
2003 5
2004 16
2005 4
2006 10
2007 13
2008 14
2009 3
2010 13
2011 12
2012 14
2013 20
2014 28
2015 33
2016 28
2017 37
2018 48
2019 55
2020 40
2021 48
2022 54
2023 63
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

549 results

Results by year

Filters applied: . Clear all
Page 1
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.
Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. Morgenstern A, et al. Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524. Curr Radiopharm. 2018. PMID: 29732998 Free PMC article. Review.
BACKGROUND: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. OBJECTIVE AND CONCLUSION: This review describes met …
BACKGROUND: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resista …
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.
Jang A, Kendi AT, Sartor O. Jang A, et al. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157632. doi: 10.1177/17588359231157632. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895851 Free PMC article. Review.
These agents have been linked to different radionuclides including beta-emitters such as lutetium-177 and alpha-emitters such as actinium-225. The only regulatory-approved PSMA-targeted radioligand therapy (PSMA-RLT) to date is lutetium-177-PSMA-617 in the setting o …
These agents have been linked to different radionuclides including beta-emitters such as lutetium-177 and alpha-emitters such …
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
Ramnaraign B, Sartor O. Ramnaraign B, et al. Oncologist. 2023 May 8;28(5):392-401. doi: 10.1093/oncolo/oyac279. Oncologist. 2023. PMID: 36806966 Free PMC article.
Older agents, seldom used today, provided palliation for bone metastatic pain. In 2013, the alpha emitter radium-223 provided a catalyst for the field by prolonging survival in men with metastatic castrate-resistant prostate cancer (mCRPC). ...Earlier phase trials ( …
Older agents, seldom used today, provided palliation for bone metastatic pain. In 2013, the alpha emitter radium-223 provided a catal …
Targeted alpha-Emitter Therapy of Neuroendocrine Tumors.
Kunikowska J, Królicki L. Kunikowska J, et al. Semin Nucl Med. 2020 Mar;50(2):171-176. doi: 10.1053/j.semnuclmed.2019.11.003. Semin Nucl Med. 2020. PMID: 32172802 Free article. Review.
Among the various therapeutic options, peptide receptor radionuclide therapy (PRRT), using somatostatine has been shown to be highly effective and a well-tolerated therapy, improving survival parameters. The current use of radionuclides for PRRT is beta-emitters. Due to hy …
Among the various therapeutic options, peptide receptor radionuclide therapy (PRRT), using somatostatine has been shown to be highly effecti …
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. Poeppel TD, et al. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12. Eur J Nucl Med Mol Imaging. 2018. PMID: 29234845 Free article.
Radium Ra-223 dichloride (radium-223, Xofigo) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. ...
Radium Ra-223 dichloride (radium-223, Xofigo) is a targeted alpha therapy approved for the treatment of castration-resistant prostate …
Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study.
Rahbar K, Essler M, Pabst KM, Eiber M, Fougère C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. J Nucl Med. 2023 Apr;64(4):574-578. doi: 10.2967/jnumed.122.264456. Epub 2022 Oct 27. J Nucl Med. 2023. PMID: 36302656 Free PMC article.
The radium lutetium (RALU) study evaluated the feasibility of sequential alpha- and beta-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. ...
The radium lutetium (RALU) study evaluated the feasibility of sequential alpha- and beta-emitter use in patients with bone-predominan …
99mTc-[Cys3,4,10,d-Phe7,Arg11]α-MSH3-13.
Cheng KT, Quinn TP. Cheng KT, et al. 2007 Jan 26 [updated 2008 Jan 22]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Jan 26 [updated 2008 Jan 22]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641499 Free Books & Documents. Review.
(99m)Tc-[Cys(3,4,10),d-Phe(7),Arg(11)]alphaMSH(3-13) ((99m)Tc-(Arg(11))CCMSH) is a radioligand developed as a single-photon emission computed tomography (SPECT) imaging probe for primary and metastatic melanoma (1). (99m)Tc-(Arg(11))CCMSH is an alpha-melanocytestimulating hormone …
(99m)Tc-[Cys(3,4,10),d-Phe(7),Arg(11)]alphaMSH(3-13) ((99m)Tc-(Arg(11))CCMSH) is a radioligand developed as a single-photon emission compute …
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K, Pomykala KL. Feuerecker B, et al. J Nucl Med. 2023 May;64(5):685-692. doi: 10.2967/jnumed.122.265353. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055224 Free article. Review.
In this review, we summarize the important studies ranging from the first Food and Drug Administration-approved alpha-therapy, (223)Ra-dichloride, for treatment of bone metastases in castration-resistant prostate cancer, including concepts in clinical translation such as t …
In this review, we summarize the important studies ranging from the first Food and Drug Administration-approved alpha-therapy, (223)Ra-dichl …
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591.
Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH. Tagawa ST, et al. J Clin Oncol. 2024 Mar 1;42(7):842-851. doi: 10.1200/JCO.23.00573. Epub 2023 Nov 3. J Clin Oncol. 2024. PMID: 37922438 Clinical Trial.
PURPOSE: Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated th …
PURPOSE: Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific …
Targeted α-therapy in non-prostate malignancies.
Jadvar H, Colletti PM. Jadvar H, et al. Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):47-53. doi: 10.1007/s00259-021-05405-0. Epub 2021 May 16. Eur J Nucl Med Mol Imaging. 2021. PMID: 33993386 Review.
Progress in unraveling the complex biology of cancer, novel developments in radiochemistry, and availability of relevant alpha-emitters for targeted therapy have provided innovative approaches to precision cancer management. The approval of (223)Ra dichloride for treatment …
Progress in unraveling the complex biology of cancer, novel developments in radiochemistry, and availability of relevant alpha-emitters …
549 results